Sorafenib (BAY 43-9006)是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,IC50分别为6 nM, 22 nM和90 nM。
1生物活性
Sorafenib (Bay 43-9006)是一种有效的多激酶抑制剂,抑制Raf-1,B-Raf和VEGFR-3的IC50值分别为6 nM,20 nM,22 nM。Sorafenib 诱导细胞自噬 (autophagy) 和凋亡 (apoptosis),并具有抗肿瘤活性。Sorafenib 也是一种 ferroptosis 激动剂。
2实验参考
3化学性质
分子量 464.82
分子式 C21H16ClF3N4O3
CAS号 284461-73-0
溶解性(25°C) DMSO 45 mg/mL
储存条件 粉末型式 -20°C 3年;4°C 2年
溶于溶剂 -80°C 6个月;-20°C 1个月
运输方式 冰袋运输,根据产品的不同,可能会有相应调整。
4储备液配置
5参考文献
[1] Qiujie Wang, et al. Cell Death Dis. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis
[2] Jialei Sun, et al. Redox Biol. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation
[3] Xin Chen, et al. Nat Rev Clin Oncol. Broadening horizons: the role of ferroptosis in cancer
[4] Scott M Wilhelm, et al. Cancer Res . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
[5] Xiufeng Jiang, et,al. Oncotarget, Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma